SRT Therapeutics has filed a notice of an exempt offering of securities to raise $47,510,731.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, SRT Therapeutics is raising up to $47,510,731.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About SRT Therapeutics
SRT Therapeutics is a San Diego-based biotech company established in 2024 by the founders of Prometheus Biosciences, Steph Targan, MD (Cedars Sinai), Janine Bilsborough, Ph.D. (Cedars Sinai), the scientific team that discovered Tulisokibart (MK7240) and the role of TL1A in IBD and Scott Glenn and Lauren Otsuki, the drug development team that took Tulisokibart (MK7240) from academia into the clinic. Building on the demonstrated success of the precision medicine approach in IBD with Tulisokibart, SRT Therapeutics will expand this approach by targeting key pathways that not only modulate inflammatory pathways, but also promote tissue healing in IBD. This strategy will move SRT Therapeutics beyond the current empirical treatment model to realize the goal of enhancing both outcomes and the quality of care for our patients.
To learn more about SRT Therapeutics, visit https://srt-tx.com/
SRT Therapeutics Linkedin Page: https://www.linkedin.com/company/srt-therapeutics-inc/
Contact:
Lauren Otsuki, President and Chief Executive Officer
858-868-7108
https://www.linkedin.com/in/lauren-otsuki-0938294b/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.